Thermo Fisher Scientific Inc. TMO said Thursday it agreed to pay $912.5 million in cash for Waltham, Mass.-based CorEvitas LLC, a provider of “regulatory-grade” evidence for approved medical treatments and therapies, from seller Audax Private Equity. Thermo Fisher said the acquisition of the 300-employee company with $110 million in projected 2023 revenue will add 3 cents a share to Thermo Fisher’s adjusted 2024 earnings. Thermo Fischer CEO Marc N. Casper said, “There is strong market demand for real-world evidence which improves decision making and reduces the time and cost associated with drug development.” The deal…
